Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXS003
- Development stage
- Phase 3
- Lead developer
- CXS Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CXS003 is a patented, low-dose fixed-dose combination of two repositioned antidiabetic drugs, metformin (CXS001) and glibenclamide (CXS002), being developed by CXS Therapeutics and its subsidiary Sappiens. It is designed as a disease-modifying, neuroprotective therapy for neurodegenerative disorders, specifically Parkinson's disease and amyotrophic lateral sclerosis (ALS). CXS003 simultaneously targets three key drivers of neurodegeneration: oxidative stress, neuroinflammation, and mitochondrial dysfunction. Preclinical studies in animal models of Parkinson's disease have demonstrated significant neuroprotective effects, including improved neuronal survival and behavioral recovery. The combination is planned to enter clinical trials in 2027, with a Phase 2 trial scheduled for 2028.
- Other names
- CSX 003CSX003CSX-003CXS 003CXS003CXS-003glibenclamide + metforminmetformin + glibenclamide
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)KATP channel (ATP-sensitive potassium channel)GPD2 (Glycerol-3-phosphate dehydrogenase 2)ND1 (Mitochondrial electron transport chain complex I)SUR1 (Sulfonylurea receptor 1)TRPM4 (Calcium-activated non-selective cation channel TRPM4)
Beyond the preview
Go deeper on CXS003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXS003.